Clinical trials
Phase 2 Adenoviridae Infections trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
18 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2005 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2012 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2021 | 3 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 5 |
| Completed | 4 |
| Terminated | 3 |
| Unknown status | 3 |
| Withdrawn | 2 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Jazz Pharmaceuticals | 2 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2 |
| Bayer | 1 |
| CG Oncology, Inc. | 1 |
| Children's Hospital Medical Center, Cincinnati | 1 |
| EpicentRx, Inc. | 1 |
| Introgen Therapeutics | 1 |
| New York Medical College | 1 |
| NovaBay Pharmaceuticals, Inc. | 1 |
| Seoul National University Bundang Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Adenoviridae Infections | 18 |
| Cytomegalovirus Infections | 2 |
| HIV Infections | 2 |
| Melanoma | 2 |
| Cardiomyopathies | 1 |
| Chondrosarcoma | 1 |
| Conjunctivitis | 1 |
| Coronavirus Infections | 1 |
| Enterovirus Infections | 1 |
| Epstein-Barr Virus Infections | 1 |
Trials
Showing 1 to 18 of 18. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.